Engineering of the Melanoma Inhibitor of Apoptosis (ML‐IAP) Anticancer Peptide Through Comprehensive In Silico Approaches
Human Mutation · 2026-01 · 2026 (1)
DOI: 10.1155/humu/9356098 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Mutation, online erschienen am 10.04.2026. Verfasst von Haitham Ahmed Al-Madhagi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Biochemical Technology Program, Thamar University, Dhamar, Yemen, thuniv.net. Hauptthemen laut MEDLINE: Melanoma, Antineoplastic Agents, Protein Engineering, Peptides. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: King Saud University.
Abstract (Originalsprache)
Background and Aims Melanoma represents the most malignant type of skin cancer. It is estimated that approximately 100,000 new cases of melanoma were diagnosed in 2022, resulting in over 7600 deaths in the United States alone. Recently, anticancer peptides (ACPs) have emerged as novel therapeutic agents for cancer, offering higher potency, biocompatibility, and fewer adverse reactions in host cells. One of the druggable targets of melanoma is the melanoma inhibitor of apoptosis (ML‐IAP), conventionally inhibited by the nonapeptide AVPIAQKSE. The current study is aimed at enhancing both the binding affinity and safety profile of this peptide through in silico peptide engineering.
Methods
Initially, the 3D structure of the protein was downloaded from the Protein Data Bank (PDB) (ID: 1OXQ) and prepared. The hotspot residues at the interface were detected using Discovery Studio Client 2021. Afterwards, saturation mutagenesis was conducted to discover the best potential amino acid substitutions with a positive impact on the binding affinity. The lead candidates were docked to the receptor via HPEPDOCK 2. Additionally, the safety profile was assessed using the ToxIBTL and AllerCatPro 2 servers. Finally, molecular dynamics simulations and principal component analysis were performed to check the stability of the best complexes.
Results
HVPIAQKSE, WVPWAQKSE, and HVPWAQKSE were the best mutants that could be superior to the original peptide in terms of binding affinity as well as safety profile. MD results confirmed the stability, flexibility, reduced local motions, conformational changes, and more compact structure upon binding the receptor for 200 ns, which deserve in vitro validation as a better melanoma ACP therapeutic option.
Conclusion
These variants displayed increased flexibility, reduced conformational alterations and local motions, and a more compact configuration, suggesting greater stability compared with the reference peptide.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biochemical Technology Program, Thamar University, Dhamar, Yemen, thuniv.net.
- Dongguan Key Laboratory of Computer-Aided Drug Design, Guangdong Provincial Key Laboratory for Research and Development of Natural Drugs, School of Pharmacy, Guangdong Medical University, Dongguan, Guangdong, China, gdm…
- State Key Laboratories of Chemical Resources Engineering, Beijing University of Chemical Technology, Beijing, China, buct.edu.cn.
- Department of Oral and Maxillofacial Surgery, University of Damascus, Damascus, Syria, damascusuniversity.edu.sy.
- Laboratory of Biology, Polydisciplinary Faculty of Safi-Cadi Ayyad University, Safi, Morocco, uiz.ac.ma.
- Department of Pharmaceutics, King Saud University, Riyadh, Saudi Arabia, ksu.edu.sa.
ORCID-Profile: Haitham Ahmed Al-Madhagi, Muhammad Shahab, Mohammed Bourhia, Gamal A Shazly, Musaab Dauelbait, Zunnan Huang
Förderung
- King Saud University
Zitieren
APA
Al-Madhagi, H. A., Shahab, M., Guojun, Z., Al-Madhagy, G., Bourhia, M., Shazly, G. A., Dauelbait, M., & Huang, Z. (2026). Engineering of the Melanoma Inhibitor of Apoptosis (ML‐IAP) Anticancer Peptide Through Comprehensive In Silico Approaches. Human Mutation, 2026(1). https://doi.org/10.1155/humu/9356098
Vancouver
Al-Madhagi HA, Shahab M, Guojun Z, Al-Madhagy G, Bourhia M, Shazly GA, et al. Engineering of the Melanoma Inhibitor of Apoptosis (ML‐IAP) Anticancer Peptide Through Comprehensive In Silico Approaches. Human Mutation. 2026;2026(1). doi:10.1155/humu/9356098
BibTeX
@article{AlMadhagi2026,
author = {Al-Madhagi, Haitham Ahmed and Shahab, Muhammad and Guojun, Zheng and Al-Madhagy, Gamil and Bourhia, Mohammed and Shazly, Gamal A and Dauelbait, Musaab and Huang, Zunnan},
title = {Engineering of the Melanoma Inhibitor of Apoptosis (ML‐IAP) Anticancer Peptide Through Comprehensive In Silico Approaches},
journal = {Human Mutation},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/humu/9356098}
}
EUVIMED